Analysis Note

ControlHeLa, HepG2, and Cos7 cell lysates

Application

Research Sub CategoryTranscription Factors

Research CategoryEpigenetics & Nuclear Function

Immunohistochemistry Analysis: A 1:200-1,000 dilution from a representative lot detected UBE2I in prostate and bladder cancer tissues.

Immunofluorescent Analysis: A 1:200-1,000 dilution from a representative lot detected UBE2I in HepG2 cells.

Flow Cytometry Analysis: A 1:200-400 dilution from a representative lot detected UBE2I in non serum starved HepG2 cells.

Optimal working dilutions must be determined by end user.

Anti-UBE2I Antibody, clone 1B10 is a highly specific mouse monoclonal antibody, that targets Ubiquitin carrier protein 9 & has been tested in western blotting, Immunofluorescence, IHC & Flow Cytometry.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

The protein encoded by the human gene UBE2I (or UBC9, UBCE9) is a SUMO conjugating enzyme, also called SUMO-protein ligase, Ubiquitin carrier protein 9, Ubiquitin carrier protein I, Ubiquitin-conjugating enzyme E2 I, Ubiquitin-protein ligase I or p18, that attaches SUMO proteins (SUMO1, SUMO2, SUMO3 & SUMO4) to other target proteins, primarily various transcription factors (HIF1A, FOXL2, KAT5, I-kappa-B) with the help of ubiquitin E3 ligases such as CBX4 and RANBP2. UBE2I is also know to interact with a huge array of additional targets as part of its role as a ubiquitin E2 ligase including SALL1, FHIT, RANBP2, Protein inhibitor of activated STAT2, DNMT3A, DNMT3B, Small ubiquitin-related modifier 1, SAE2,RANGAP1,Death associated protein 6, Androgen receptor, ETS1, IPO13, TCF3, TNFRSF1A, DACH1, P53, BLMH, MAP3K1, WT1, TOP1, RAD51, Activating transcription factor 2, and PIAS1. UBE2I expression is largely nuclear and the protein can be found expressed in a wide variety of tissues including heart, skeletal muscle, pancreas, kidney, liver, lung, testis, thymus, placenta and brain. EMD-Millipore's Anti-UBE2I mouse monoclonal antibody has been tested in western blot on recombinant UBE2I protein as well as HeLa, HepG2 and COS7 cell lysates and in paraffin embedded immunohistochemistry on normal prostate and bladder cancer tissue sections. The antibody has also been successfully tested in fluorescent immunocytochemistry on HepG2 cells in culture and in flow cytometry on HepG2 cells in culture.

Immunogen

Purified recombinant fragment of human UBE2I expressed in E. Coli.

Physical form

Mouse monoclonal IgG1 ascitic fluid containing up to 0.1% sodium azide.

Unpurified

Quality

Evaluated by Western Blotting in HeLa, HepG2, and Cos7 cell lysates.

Western Blotting Analysis: A 1:500-2,000 dilution of this antibody detected UBE2I in HeLa, HepG2, and Cos7 cell lysates.

Storage and Stability

Stable for 1 year at -20°C from date of receipt.
Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.

Target description

~18 kDa observed. Uncharacterized bands may appear in some lysate(s).